$104 Million is the total value of Opus Point Partners Management, LLC's 43 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was 36.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMY | Sell | BRISTOL MYERS SQUIBB CO | $5,274,000 | +7.1% | 71,703 | -7.0% | 5.09% | +33.8% |
| MRK | Sell | MERCK & CO INC | $4,822,000 | +1.3% | 83,700 | -7.0% | 4.66% | +26.5% |
| ALKS | Sell | ALKERMES PLC | $3,581,000 | +2.4% | 82,858 | -19.0% | 3.46% | +27.9% |
| MDVN | Sell | MEDIVATION INC | $3,109,000 | -36.4% | 51,561 | -51.5% | 3.00% | -20.6% |
| SGEN | Sell | SEATTLE GENETICS INC | $2,994,000 | -22.4% | 74,093 | -32.6% | 2.89% | -3.0% |
| AMGN | Sell | AMGEN INC | $2,833,000 | -30.5% | 18,619 | -31.5% | 2.74% | -13.2% |
| INCY | Sell | INCYTE CORP | $2,818,000 | -24.8% | 35,237 | -31.8% | 2.72% | -6.0% |
| ILMN | Sell | ILLUMINA INC | $2,631,000 | -25.3% | 18,741 | -13.8% | 2.54% | -6.7% |
| MTD | Sell | METTLER TOLEDO INTERNATIONAL | $2,623,000 | -19.9% | 7,188 | -24.3% | 2.53% | +0.0% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $2,602,000 | -20.4% | 30,248 | -26.5% | 2.51% | -0.6% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $2,540,000 | -35.9% | 178,531 | -38.0% | 2.45% | -19.9% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $2,526,000 | -21.5% | 7,233 | -19.0% | 2.44% | -1.9% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $2,424,000 | -50.2% | 43,684 | -43.7% | 2.34% | -37.8% |
| QGEN | Sell | QIAGEN NV | $2,306,000 | -23.5% | 105,751 | -21.7% | 2.23% | -4.5% |
| CELG | Sell | CELGENE CORP | $2,262,000 | -42.9% | 22,932 | -42.1% | 2.18% | -28.7% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $2,250,000 | -43.5% | 28,915 | -40.1% | 2.17% | -29.4% |
| BIIB | Sell | BIOGEN INC | $2,187,000 | -24.5% | 9,042 | -18.7% | 2.11% | -5.7% |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $2,020,000 | -42.9% | 17,301 | -31.9% | 1.95% | -28.6% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $1,814,000 | -12.4% | 43,295 | -15.1% | 1.75% | +9.4% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $1,651,000 | -57.9% | 70,868 | -26.8% | 1.60% | -47.4% |
| SNR | Sell | NEW SR INVT GROUP INC | $894,000 | -3.6% | 83,700 | -7.0% | 0.86% | +20.4% |
| SDS | Sell | PROSHARES TR | $712,000 | -16.5% | 40,000 | -11.1% | 0.69% | +4.4% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $684,000 | -12.4% | 45,198 | -16.3% | 0.66% | +9.4% |
| MCRB | Sell | SERES THERAPEUTICS INC | $591,000 | -8.4% | 20,339 | -16.3% | 0.57% | +14.4% |
| HOLX | Sell | HOLOGIC INC | $571,000 | -57.2% | 16,500 | -57.4% | 0.55% | -46.6% |
| PRTK | Sell | PARATEK PHARMACEUTICALS INC | $524,000 | -23.3% | 37,665 | -16.3% | 0.51% | -4.2% |
| MDCO | Sell | MEDICINES CO | $467,000 | -63.7% | 13,885 | -65.7% | 0.45% | -54.7% |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $346,000 | -59.5% | 7,074 | -47.6% | 0.33% | -49.5% |
| OPHT | Sell | OPHTHOTECH CORP | $344,000 | -35.5% | 6,746 | -46.5% | 0.33% | -19.4% |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $219,000 | -49.0% | 2,064 | -46.4% | 0.21% | -36.1% |
| AXGT | Sell | AXOVANT SCIENCES LTD | $172,000 | -43.2% | 13,389 | -49.3% | 0.17% | -29.1% |
| GILD | Exit | GILEAD SCIENCES INC | $0 | – | -3,282 | -100.0% | -0.23% | – |
| FLDM | Exit | FLUIDIGM CORP DEL | $0 | – | -45,000 | -100.0% | -0.28% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -49,500 | -100.0% | -0.34% | – |
| PSDV | Exit | PSIVIDA CORP | $0 | – | -180,000 | -100.0% | -0.37% | – |
| RXDX | Exit | IGNYTA INC | $0 | – | -81,000 | -100.0% | -0.42% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -108,000 | -100.0% | -0.45% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -68,130 | -100.0% | -0.49% | – |
| MACK | Exit | MERRIMACK PHARMACEUTICALS IN | $0 | – | -90,000 | -100.0% | -0.58% | – |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -69,109 | -100.0% | -0.59% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS IN | $0 | – | -99,000 | -100.0% | -0.59% | – |
| ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -31,500 | -100.0% | -0.72% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -36,000 | -100.0% | -0.76% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -75,000 | -100.0% | -1.11% | – |
| VCEL | Exit | VERICEL CORP | $0 | – | -298,941 | -100.0% | -1.35% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -35,110 | -100.0% | -1.44% | – |
| EPZM | Exit | EPIZYME INC | $0 | – | -189,564 | -100.0% | -1.78% | – |
| BIB | Exit | PROSHARES TR | $0 | – | -64,462 | -100.0% | -2.04% | – |
| IWM | Exit | ISHARES TRput | $0 | – | -200,000 | -100.0% | -17.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-08-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.